Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia

Yilmaz, BT; Alioglu, B; Ozyurek, E; Akay, HT; Mercan, S; Ozbek, N

doi:10.1007/s00246-004-0919-7

Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia

Yilmaz B., Alioglu B., Ozyurek E., Akay H., Mercan S., Ozbek N.

PEDIATRIC CARDIOLOGY, cilt.26, sa.6, ss.843-845, 2005 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26 Sayı: 6
Basım Tarihi: 2005
Doi Numarası: 10.1007/s00246-004-0919-7
Dergi Adı: PEDIATRIC CARDIOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.843-845
Anahtar Kelimeler: recombinant factor VIIa, cardiopulmonary bypass, cardiac surgery, Glanzmann thrombasthenia, ACTIVATED FACTOR-VII, CONTINUOUS-INFUSION, MANAGEMENT, INHIBITOR, EFFICACY, RFVIIA
Ankara Üniversitesi Adresli: Hayır

Özet

Glanzmann thrombasthenia is a rare, hereditary, congenital disorder of platelet function characterized by inappropriate bleeding that is difficult to control. Recombinant activated factor VII (rFVIIa) is a new treatment that is used to stop bleeding and provide surgical support for these patients. This report describes the use of rFVIIa to prevent serious bleeding during and after open-heart surgery in a child with Glanzmann thrombasthenia.